After a period of revamping a venture strategy gone wrong, Atlas Venture has come out today with news about an oversubscribed 9 th fund of $265 million. It's a rare comeback story in a VC industry that is suffering from an overall lack of capital to fuel startups in biotech and other high-risk-and-reward sectors.
Topera first disclosed its $25 million Series C financing in a regulatory filing in March, but now it's revealing the investors behind the deal, and the lead one is a big fish indeed--New Enterprise Associates.
Ask any biotech exec in the business of drug and device development about the funding environment these days, and you'll most likely hear the word "tough" inside of three seconds. The...
David Mott, ex-CEO of MedImmune and a high-profile biotech partner at New Enterprise Associates, has led the way toward an orphan drug accelerator also backed by Pfizer Ventures.
David Mott at New Enterprise Associates has spearheaded the development of an orphan drug accelerator that plans to hunt down the best in vivo-stage assets in academia, biopharma and the nonprofits, assemble them in a portfolio of rare disease therapies and mold them into pipeline programs that can be spun out into a slate of new biotech companies.
Closing in on the selection of its lead cancer program, San Francisco-based Cleave Biosciences has welcomed the deep-pocketed player New Enterprise Associates to its list of venture backers and topped up its Series A with a $10 million investment in its early-stage drug research work.
Nevro, a 2012 Fierce 15 company, has pulled down $48 million more in venture financing, money it will use to buoy its pain-management implant toward FDA approval.
The world's biggest biotechs are piling up data by the petabyte, amassing numbers for gene expression, biomarker reliability, patient outcomes and pretty much every other measurable vector in drug development. Of course, to date, no disease has ever been treated by a spreadsheet, so how do we take Big Data from the server closet to the doctor's office?
In a move to expand, personal genomics company 23andMe has rallied investors for a $50 million Series D round of financing. The fourth-round financing came with news that the company, which had offered its personal genetic test for about $300, is cutting the price to $99.
With a lead candidate in development for a big cardio market, Cardioxyl Pharmaceuticals has wrapped up a $28.1 million round of equity financing, according to an SEC filing this week. The disclosure follows years of work on a candidate in mid-stage development for acute decompensated heart failure.